
AtriCure (ATRC) Stock Forecast & Price Target
AtriCure (ATRC) Analyst Ratings
Bulls say
AtriCure is set to benefit fromtheir strong financial position as they continue to invest in research and development and expanding their international presence through direct sales and acquisitions. AtriCure is actively targeting a growing market for their open ablation treatment, with the potential to significantly increase their revenue and market share by 2030. The company is also positioned to benefit from new quality measures and the STS Star rating system, which could expand their treatment of pre-operative AF cases. Despite facing industry risks, AtriCure's strong financial position and consistent growth plans make them a recommended "buy" alongside other successful medical technology companies.
Bears say
AtriCure is a Buy based on its strong potential upside and profitability in the core business, driven by the growth in open-heart surgery and its AtriClip and Open Ablation franchise. There is also potential for contribution from new verticals like cryoablation. With a price target of $45 based on a 3x revenue estimate, there is significant opportunity for growth and a positive outlook for the company despite risks such as competition and shifts in market share.
This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.
AtriCure (ATRC) Analyst Forecast & Price Prediction
Start investing in AtriCure (ATRC)
Order type
Buy in
Order amount
Est. shares
0 shares